Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Mepolizumab significantly improved outcomes in patients with CRSwNP who had 1 or more previous surgeries for nasal polyps.

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...